Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. possesses a strong position in the oncology market, particularly due to the promising clinical trials of Z-endoxifen, which has demonstrated efficacy and safety across multiple indications in breast cancer, specifically showing numerically superior results compared to tamoxifen. The company’s strategic focus on metastatic breast cancer and the validation from interactions with regulatory consultants and key opinion leaders further enhances its prospects, positioning it favorably within a competitive landscape. Additionally, the potential for broader application of Z-endoxifen across various patient populations, combined with ongoing development of its COVID-19 therapeutics, underlines the company’s commitment to addressing high unmet medical needs, which may provide significant upside for stakeholders.

Bears say

Atossa Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily related to safety and efficacy concerns surrounding its clinical and preclinical programs. The company anticipates needing approximately $275 million in additional financing through 2037 to maintain operations, with a cash runway projected only into the second half of 2026. Furthermore, potential regulatory challenges, intellectual property issues, and the risk of de-listing should the stock price fall below $1 exacerbate the financial uncertainties impacting investor confidence.

Atossa Genetics (ATOS) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.